Education
About Us
Working with TipRanks
Follow Us
Star Combo Pharma Ltd. (AU:S66)
ASX:S66
S66 Stock Chart & Stats
AU$0.25
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.25
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.28
Previous CloseN/A
Volume100.00K
Average Volume (3M)6.77K
Market Cap
AU$27.68M
Enterprise ValueAU$31.89M
Total Cash (Recent Filing)AU$18.18M
Total Debt (Recent Filing)AU$8.29M
Price to Earnings (P/E)21.2
Beta-0.60
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.86
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationFree cash flow growth of 178.51% and an operating cash flow to net income ratio of 2.04 indicate durable cash conversion. Strong cash generation supports reinvestment, dividends and a buffer against downturns, giving the company strategic flexibility over months.
Conservative Balance SheetA debt-to-equity ratio of 0.10 and an improved ROE of 13.78% point to low leverage and better shareholder returns. Conservative capital structure reduces financial distress risk and preserves capacity for capex or opportunistic investments over the medium term.
Improving MarginsGross margin at 22.55% and net margin at 18.87% reflect improved cost management and higher profitability. If sustained, these margin gains support ongoing cash generation and resilience to revenue volatility, improving the company's ability to fund growth and returns.
Bears Say
Revenue DeclineRevenue fell by 6.34% in the latest year, indicating weakening top-line momentum. Continued sales contraction limits operating leverage, reduces reinvestment capacity, and forces reliance on margin fixes or non-recurring items to sustain profits over the medium term.
Negative Operating MarginA persistently negative EBIT margin shows core operations are not yet profit-generating despite reported net income gains. Reliance on non-operating items or one-offs to reach net profitability raises risk that operating losses could re-emerge if those items reverse.
Earnings Volatility / QualityEPS growth of ~504% alongside a ‘substantial rise in net income’ suggests earnings were materially affected by non-recurring items. This volatility reduces predictability of recurring earnings and complicates forecasting and assessment of sustainable cash flows.
Star Combo Pharma Ltd. News
S66 FAQ
What was Star Combo Pharma Ltd.’s price range in the past 12 months?
Star Combo Pharma Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.
What is Star Combo Pharma Ltd.’s market cap?
Star Combo Pharma Ltd.’s market cap is AU$27.68M.
When is Star Combo Pharma Ltd.’s upcoming earnings report date?
Star Combo Pharma Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 172 days.
How were Star Combo Pharma Ltd.’s earnings last quarter?
Star Combo Pharma Ltd. released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Star Combo Pharma Ltd. overvalued?
According to Wall Street analysts Star Combo Pharma Ltd.’s price is currently Overvalued.
Does Star Combo Pharma Ltd. pay dividends?
Star Combo Pharma Ltd. pays a Notavailable dividend of AU$0.004 which represents an annual dividend yield of 1.54%. See more information on Star Combo Pharma Ltd. dividends here
What is Star Combo Pharma Ltd.’s EPS estimate?
Star Combo Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Star Combo Pharma Ltd. have?
Star Combo Pharma Ltd. has 135,002,980 shares outstanding.
What happened to Star Combo Pharma Ltd.’s price movement after its last earnings report?
Star Combo Pharma Ltd. reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Star Combo Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:S66
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Star Combo Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.20%
12-Months-Change
Fundamentals
Return on Equity
14.70%
Trailing 12-Months
Asset Growth
13.16%
Trailing 12-Months
Company Description
Star Combo Pharma Ltd.
Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. The company operates in two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products. The company provides its products through e-commerce platform to Chinese health product consumers; and two retail stores in Sydney. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Technical Analysis
Zoono Group Limited
―
Nanollose Ltd.
―
Skin Elements Limited
―
Lumos Diagnostics Holdings Ltd.
―
―